If you continue without changing your settings, we’ll assume you’re happy to receive all cookies from the BMA website. Find out more about cookies
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalised web experience.
Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.
You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
These cookies are required
These cookies allow us to know which pages are the most and least popular and see how visitors move around the site. All information we collect is anonymous unless you actively provide personal information to us.
If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
These cookies allow a website to remember choices you make (such as your user name, language or the region you're in) and tailor the website to provide enhanced features and content for you.
For example, they can be used to remember certain log-in details, changes you've made to text size, font and other parts of pages that you can customise. They may also be used to provide services you've asked for such as watching a video or commenting on a blog. These cookies may be used to ensure that all our services and communications are relevant to you. The information these cookies collect cannot track your browsing activity on other websites.
Without these cookies, a website cannot remember choices you've previously made or personalise your browsing experience meaning you would have to reset these for every visit. In addition, some functionality may not be available if this category is switched off.
Our websites sometimes integrate with other companies’ sites. For example, we integrate with social networking sites such as Twitter and Facebook, to make it easier for you to share what you have read. These sites place their own cookies on your browser as a result of us including their icons and ‘like’ or ‘share’ buttons on our sites.
Professor Sarosh Irani is an Associate Professor, Consultant Neurologist and Wellcome Trust Clinical Fellow at Oxford University
In 2013 Professor Irani won the BMA Vera Down grant for research into neurological disease. Here he explains the vital impact of his project:
Encephalitis is a serious condition affecting 6000 people in the UK every year. Anyone can be affected including the very old and the very young. The syndrome of encephalitis is inflammation of the brain and is associated with rapid onset of memory lost, seizures and loss of movement in parts of the body.
While traditionally thought to be caused by viruses, recently it has become clear that encephalitis can frequently be due to a patients’ own antibodies accessing their brain. These antibodies can be detected in patients’ blood and spinal fluid as diagnostic markers. Importantly, antibodies may be effectively removed with available therapies and this removal often corresponds closely with clinical improvement. In fact, some patients make an almost complete recovery from a condition which may otherwise produce long-term seizures with mental impairment.
Despite these discoveries, many patients with encephalitis still have no known cause. Furthermore, we know that some adults with unexplained forms of epilepsy harbour the same antibodies, suggesting our knowledge about encephalitis has the potential to improve the lives of people with other neurological diseases.
The funding received from the BMA foundation has enabled a project which aims to identify antibodies from the blood and spinal fluid of patients with unexplained forms of encephalitis, and forms of epilepsy. We have had success with our recent discovery of a particular antibody, and we are currently searching for other novel antibody targets.
We are proud of the part our research has played in providing hope that more patients will be able to make a full recovery from this debilitating syndrome.